EP2804952A4 - Stabilisation de l'anticorps anti-cd20 rituximab - Google Patents

Stabilisation de l'anticorps anti-cd20 rituximab

Info

Publication number
EP2804952A4
EP2804952A4 EP12865606.3A EP12865606A EP2804952A4 EP 2804952 A4 EP2804952 A4 EP 2804952A4 EP 12865606 A EP12865606 A EP 12865606A EP 2804952 A4 EP2804952 A4 EP 2804952A4
Authority
EP
European Patent Office
Prior art keywords
stabilization
antibody rituximab
rituximab
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12865606.3A
Other languages
German (de)
English (en)
Other versions
EP2804952A2 (fr
Inventor
Rosemarie Wilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Proteins International LLC
Original Assignee
Therapeutic Proteins International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Proteins International LLC filed Critical Therapeutic Proteins International LLC
Publication of EP2804952A2 publication Critical patent/EP2804952A2/fr
Publication of EP2804952A4 publication Critical patent/EP2804952A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP12865606.3A 2012-01-19 2012-01-19 Stabilisation de l'anticorps anti-cd20 rituximab Withdrawn EP2804952A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/021888 WO2013109279A2 (fr) 2012-01-19 2012-01-19 Stabilisation de l'anticorps anti-cd20 rituximab

Publications (2)

Publication Number Publication Date
EP2804952A2 EP2804952A2 (fr) 2014-11-26
EP2804952A4 true EP2804952A4 (fr) 2015-09-09

Family

ID=48799789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12865606.3A Withdrawn EP2804952A4 (fr) 2012-01-19 2012-01-19 Stabilisation de l'anticorps anti-cd20 rituximab

Country Status (7)

Country Link
EP (1) EP2804952A4 (fr)
JP (1) JP2015506687A (fr)
CN (1) CN104204217A (fr)
AU (1) AU2012366290A1 (fr)
CA (1) CA2861428A1 (fr)
HK (1) HK1203561A1 (fr)
WO (1) WO2013109279A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150008082A (ko) * 2012-04-27 2015-01-21 바이오아트라, 엘엘씨 수정된 항체 영역 및 그의 용도
US20140377253A1 (en) * 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
CA2938193C (fr) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Moyens et procedes de production d'anticorps stables
EA201891800A1 (ru) * 2016-02-10 2019-01-31 Кайман Кемикал Компани Инкорпорейтед Антитела к цитруллинированным hla-полипептидам и их применение
CN107987160A (zh) * 2016-10-26 2018-05-04 无锡科捷诺生物科技有限责任公司 一种无岩藻糖基化的单克隆抗体
US12463463B2 (en) * 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2021041300A2 (fr) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Anticorps bispécifiques et leurs utilisations
CA3165514A1 (fr) * 2019-12-31 2021-07-08 Navrogen, Inc. Composition et utilisation d'anticorps monoclonaux anti-cd20 modifies refractaires au facteur d'immunosuppression tumorale ca125/muc16

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075110A2 (fr) * 2000-03-30 2001-10-11 Dyax Corp. Elements de liaison specifiques de la mucine-1 et techniques d'utilisation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7232888B2 (en) * 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
TWI335821B (en) * 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CN101921340A (zh) * 2004-03-31 2010-12-22 佳能株式会社 一种蛋白质
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
US20110130324A1 (en) * 2008-07-14 2011-06-02 Uchicago Argonne, Llc Methods for systematic control of protein stability
CN102159243B (zh) * 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EWERT S ET AL: "Biophysical Properties of Human Antibody Variable Domains", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 325, no. 3, 17 January 2003 (2003-01-17), pages 531 - 553, XP027180832, ISSN: 0022-2836, [retrieved on 20030117], DOI: 10.1016/S0022-2836(02)01237-8 *
KASHMIRI S V S ET AL: "SDR grafting-a new approach to antibody humanization", METHODS, ACADEMIC PRESS, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 25 - 34, XP027216560, ISSN: 1046-2023, [retrieved on 20050419] *
MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732 - 745, XP002242391, ISSN: 0022-2836, DOI: 10.1006/JMBI.1996.0548 *

Also Published As

Publication number Publication date
WO2013109279A3 (fr) 2014-04-17
WO2013109279A2 (fr) 2013-07-25
CA2861428A1 (fr) 2013-07-25
AU2012366290A1 (en) 2014-08-07
HK1203561A1 (en) 2015-10-30
CN104204217A (zh) 2014-12-10
EP2804952A2 (fr) 2014-11-26
JP2015506687A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
IL235985A0 (en) Immunoconjugates containing anti-cd22 antibodies
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
ZA201504131B (en) Fragrance materials
IL233482B (en) Stabilized formulations that include anti-ang2 antibodies
IL235989A0 (en) Immunoprecipitates containing anti–cd79b antibodies
ZA201500457B (en) Anti-kit antibodies and uses thereof
IL235987A0 (en) Immunoconjugates containing anti-cd22 antibodies
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
EP2841459A4 (fr) Anticorps anti-cd22
ZA201507844B (en) Bottle having axially opposed frustoconical portions
EP2804952A4 (fr) Stabilisation de l'anticorps anti-cd20 rituximab
ZA201408213B (en) Anti-transglutaminase 2 antibodies
GB201312226D0 (en) Improved antibodies
GB201307233D0 (en) Compounds and uses thereof
SG11201602869XA (en) Probiotic stabilization
LT3027606T (lt) Kognityvinę funkciją stiprinantys junginiai
AU356544S (en) Fragrance bottle
AU356535S (en) Fragrance bottle
AU356541S (en) Fragrance bottle
GB201304888D0 (en) Improved bottle
GB201322425D0 (en) Novel compounds and improved treatemtns for glaucoma
ZA201404909B (en) Stabilized formulations containing anti-ang2 antibodies
GB201209584D0 (en) Modified antibodies
AU356542S (en) Fragrance bottle
GB201311051D0 (en) Fastening regions of material together

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140715

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150807

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/08 20060101AFI20150803BHEP

Ipc: C07K 16/00 20060101ALI20150803BHEP

Ipc: A61K 39/00 20060101ALI20150803BHEP

Ipc: C07K 16/28 20060101ALI20150803BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203561

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170124

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203561

Country of ref document: HK